Evaluation of the dosimetry approaches in ablation treatment of thyroid cancer

por Alan Selcuk, Nalan, Toklu, Turkay, Beykan, Seval, Karaaslan, Serife Ipek
Publicado 2018

In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry

por Beykan, Seval, Fani, Melpomeni, Jensen, Svend Borup, Nicolas, Guillaume, Wild, Damian, Kaufmann, Jens, Lassmann, Michael
Publicado 2019

(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model

por Beykan, Seval, Dam, Jan S., Eberlein, Uta, Kaufmann, Jens, Kjærgaard, Benedict, Jødal, Lars, Bouterfa, Hakim, Bejot, Romain, Lassmann, Michael, Jensen, Svend Borup
Publicado 2016

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy

por Werner, Rudolf A., Beykan, Seval, Higuchi, Takahiro, Lückerath, Katharina, Weich, Alexander, Scheurlen, Michael, Bluemel, Christina, Herrmann, Ken, Buck, Andreas K., Lassmann, Michael, Lapa, Constantin, Hänscheid, Heribert
Publicado 2016

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent

por Schottelius, Margret, Osl, Theresa, Poschenrieder, Andreas, Hoffmann, Frauke, Beykan, Seval, Hänscheid, Heribert, Schirbel, Andreas, Buck, Andreas K., Kropf, Saskia, Schwaiger, Markus, Keller, Ulrich, Lassmann, Michael, Wester, Hans-Jürgen
Publicado 2017